I believe many of you have not been in MDG in 2007, but here is one of their Nrs that is worth revisting.

We will be the ONLY Company known that will have their animal studies for H1N1 this month. If they work on mice, watchout as we break to new year highs.

Medicago Announces Additional Positive Results for its H5N1 Avian Influenza VLP vaccine

- Preclinical results demonstrate effectiveness of vaccine even at extremely low doses -

Quebec City, Quebec, November 20, 2007 — Medicago Inc. (TSX-V: MDG) today announced additional positive

results from a preclinical study of its H5N1 Influenza Virus-Like Particles (“VLP”) vaccine. Medicago previously

reported that its proprietary VLP vaccine stimulates a significant seroprotective immune response against the lethal

Indonesia strain of the H5N1 Avian Influenza virus in mice who received doses as low as 1 microgram (ug). The

Company has now generated additional data showing that a strong protective immune response is achieved against

this virus at even lower doses of only 0.1 ug.

“These unprecedented data position Medicago at the forefront of influenza vaccine development,” said Andy Sheldon,

President and CEO. “A typical dose for a pandemic flu vaccine is 15-30 ug. If we are able to reproduce these results in

human clinical trials, our technology has the potential to significantly increase the world’s currently limited vaccine

manufacturing capacity, allowing for the protection of a greater number of people in the event of a pandemic influenza

outbreak.”

“This 0.1ug dose is amongst the lowest doses ever recorded,” said Dr. Louis Vezina, Medicago’s Chief Scientific

Officer. “At this very low dose, Medicago’s VLP vaccine generated neutralizing antibody levels in mice three times

higher than the minimal level required to obtain protection against an influenza infection. Based on these results, we

will continue studies to determine the lowest effective dose”